2026 Global: Breast Cancer Therapeutics-Competitive Review (2032) report
Description
The 2026 Global: Breast Cancer Therapeutics-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for breast cancer therapeutics by geography and historical trend. The scope of the report extends to sizing of the breast cancer therapeutics market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche, Novartis, AstraZeneca, Pfizer, Eli Lilly, Bristol Myers Squibb, Seagen, GlaxoSmithKline (GSK), AbbVie, and Eisai are among the ten major companies driving advances in breast cancer therapeutics through targeted antibodies, small molecules, antibody‑drug conjugates (ADCs), PARP inhibitors, CDK4/6 inhibitors, and immunotherapies. Roche’s long-established HER2 portfolio—Herceptin, Perjeta, Kadcyla—and continued investment in ADCs and immuno‑oncology keep it central to HER2‑positive treatment and diagnostics integration. Novartis anchors its breast cancer presence with Kisqali (ribociclib) and other targeted agents, expanding options for HR+/HER2‑ disease and growing its oncology revenue through both established drugs and pipeline assets. AstraZeneca has rapidly expanded in breast oncology with Enhertu (trastuzumab deruxtecan) for HER2‑positive and HER2‑low tumors and Lynparza (olaparib) for BRCA‑mutated disease, pairing ADC innovation with PARP biology and combination immunotherapy programs. Pfizer’s oncology footprint includes Ibrance (palbociclib) for HR+ advanced breast cancer and collaborations that extend its targeted and precision oncology reach, supporting large global uptake and continued lifecycle work. Eli Lilly’s Verzenio (abemaciclib) positions the company strongly in CDK4/6 inhibition for HR+/HER2‑ settings, while Lilly pursues expansions into earlier disease stages and combination strategies to sustain clinical impact.
Bristol Myers Squibb leverages immuno‑oncology expertise—checkpoint inhibitors and combination regimens—to pursue breast cancer niches and collaborates widely with biotechs to broaden indications and next‑generation modalities. Seagen specializes in ADCs and targeted small molecules, advancing tucatinib (Tukysa) for HER2‑positive disease with particular activity in brain metastases and partnering to develop novel ADC combinations that address HER2‑low and resistant tumors. GSK contributes targeted therapies and combinations, historically with agents such as lapatinib (Tykerb) and ongoing R&D into targeted and immune‑modulating approaches for specific breast cancer subtypes. AbbVie, benefiting from a broad oncology portfolio and dealmaking, pursues antibody‑based and small‑molecule programs applicable to breast cancer while integrating acquired assets to accelerate translational progress. Eisai’s Halaven (eribulin) remains an important option for heavily pretreated metastatic breast cancer, and the company continues to explore novel chemotherapeutic and targeted regimens to improve survival and tolerability in advanced settings.
Collectively these ten firms shape current standards of care and the near‑term pipeline: ADCs (notably Enhertu and Seagen partnerships), CDK4/6 inhibitors (Ibrance, Kisqali, Verzenio), PARP inhibitors (Lynparza), HER2‑directed antibodies and biosimilars, and immunotherapy combinations dominate R&D priorities, while strategic alliances and acquisitions accelerate access to novel mechanisms like targeted protein degradation, bispecifics, and tumor‑activated biologics. Market leadership is reinforced by global commercial infrastructure, extensive late‑stage clinical programs, and manufacturing scale that enable rapid adoption of new approvals and broadened indications across early and metastatic breast cancer populations.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for breast cancer therapeutics by geography and historical trend. The scope of the report extends to sizing of the breast cancer therapeutics market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Roche, Novartis, AstraZeneca, Pfizer, Eli Lilly, Bristol Myers Squibb, Seagen, GlaxoSmithKline (GSK), AbbVie, and Eisai are among the ten major companies driving advances in breast cancer therapeutics through targeted antibodies, small molecules, antibody‑drug conjugates (ADCs), PARP inhibitors, CDK4/6 inhibitors, and immunotherapies. Roche’s long-established HER2 portfolio—Herceptin, Perjeta, Kadcyla—and continued investment in ADCs and immuno‑oncology keep it central to HER2‑positive treatment and diagnostics integration. Novartis anchors its breast cancer presence with Kisqali (ribociclib) and other targeted agents, expanding options for HR+/HER2‑ disease and growing its oncology revenue through both established drugs and pipeline assets. AstraZeneca has rapidly expanded in breast oncology with Enhertu (trastuzumab deruxtecan) for HER2‑positive and HER2‑low tumors and Lynparza (olaparib) for BRCA‑mutated disease, pairing ADC innovation with PARP biology and combination immunotherapy programs. Pfizer’s oncology footprint includes Ibrance (palbociclib) for HR+ advanced breast cancer and collaborations that extend its targeted and precision oncology reach, supporting large global uptake and continued lifecycle work. Eli Lilly’s Verzenio (abemaciclib) positions the company strongly in CDK4/6 inhibition for HR+/HER2‑ settings, while Lilly pursues expansions into earlier disease stages and combination strategies to sustain clinical impact.
Bristol Myers Squibb leverages immuno‑oncology expertise—checkpoint inhibitors and combination regimens—to pursue breast cancer niches and collaborates widely with biotechs to broaden indications and next‑generation modalities. Seagen specializes in ADCs and targeted small molecules, advancing tucatinib (Tukysa) for HER2‑positive disease with particular activity in brain metastases and partnering to develop novel ADC combinations that address HER2‑low and resistant tumors. GSK contributes targeted therapies and combinations, historically with agents such as lapatinib (Tykerb) and ongoing R&D into targeted and immune‑modulating approaches for specific breast cancer subtypes. AbbVie, benefiting from a broad oncology portfolio and dealmaking, pursues antibody‑based and small‑molecule programs applicable to breast cancer while integrating acquired assets to accelerate translational progress. Eisai’s Halaven (eribulin) remains an important option for heavily pretreated metastatic breast cancer, and the company continues to explore novel chemotherapeutic and targeted regimens to improve survival and tolerability in advanced settings.
Collectively these ten firms shape current standards of care and the near‑term pipeline: ADCs (notably Enhertu and Seagen partnerships), CDK4/6 inhibitors (Ibrance, Kisqali, Verzenio), PARP inhibitors (Lynparza), HER2‑directed antibodies and biosimilars, and immunotherapy combinations dominate R&D priorities, while strategic alliances and acquisitions accelerate access to novel mechanisms like targeted protein degradation, bispecifics, and tumor‑activated biologics. Market leadership is reinforced by global commercial infrastructure, extensive late‑stage clinical programs, and manufacturing scale that enable rapid adoption of new approvals and broadened indications across early and metastatic breast cancer populations.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.